Aim: Periodontal therapy has been shown to reduce glycated haemoglobin in patients with diabetes, although considerable uncertainty remains regarding the sustainability of such changes. We evaluate the cost-effectiveness of non-surgical periodontal therapy and rigorous maintenance treatment in patients with type 2 diabetes and periodontitis from a provider perspective in the UK.
| INTRODUCTION
There is growing evidence of a link between inflammation of the periodontium and raised glycated haemoglobin levels in patients with type 2 diabetes mellitus (T2DM) (Chapple & Genco, 2013) . Prevalence of periodontal disease is higher in patients diagnosed with T2DM (Apoorva, Sridhar, & Suchetha, 2013; Garcia, Tarima, & Okunseri, 2015) . Chronic periodontal infection and the resultant inflammatory response may increase levels of glycated haemoglobin or HbA1c, a measure of long-term blood glucose levels (Borgnakke, Ylostalo, Taylor, & Genco, 2013) . The potential consequences of long-term raised HbA1c levels may be severe -micro and macro vascular complications leading to increased cardiovascular risk, blindness, amputations, renal failure and premature death (Nathan, 1993) .
Approximately £8.8 billion was spent on the treatment of T2DM in 2010/11 (Hex, Bartlett, Wright, Taylor, & Varley, 2012) . Clinical guidelines for management of T2DM include recommendations for patient education, blood pressure management, blood glucose management and management of complications such as gastroparesis, neuropathy, and renal disease, but make no mention of periodontal disease (National Institute for Health and Care Excellence, 2016) . These guidelines are based on assessment of the clinical and cost-effectiveness of interventions to control circulating blood sugars and other cardiovascular risk factors, and interventions to manage the symptoms of T2DM.
The clinical evidence linking HbA1c and periodontal disease in T2DM patients suggests a role for treatment of periodontal disease in the management of T2DM (Botero, Rodriguez, & Agudelo-Suarez, 2016; Faggion, Cullinan, & Atieh, 2016) . However, control of periodontal disease requires a lifetime maintenance programme which is not cheap (Martin et al., 2014) . Whilst treatment of periodontal disease can manifestly improve oral health, the impact on general health related quality of life (QOL) remains to be demonstrated. This study evaluates the cost-utility of non-surgical periodontal therapy for patients with periodontal disease newly diagnosed with T2DM. Cost-utility studies are a subset of cost-effectiveness studies in which the measure of effectiveness is a utility measure (in this case Quality Adjusted Life-Years or QALYs [Vergel & Sculpher, 2008] ). We draw on existing evidence of the impact of periodontal therapy in arresting tooth loss and on HbA1c levels. We utilise a clinical model of T2DM to estimate the impact of periodontal therapy on costs and QOL relating to T2DM.
The resultant estimates of cost-effectiveness are compared against thresholds considered acceptable in the UK (McCabe, Claxton, & Culyer, 2008) .
| METHODS
A spread-sheet model was constructed to estimate the lifetime costs and consequences of periodontal therapy for a patient with newly diagnosed T2DM and periodontal disease not previously receiving regular periodontal maintenance. The model included the impact on health care costs and QOL of a decrease in HbA1c attributable to periodontal treatment. The model allowed determination of the overall increased cost of treating periodontal disease in patients with T2DM per unit improvement in quality adjusted life expectancy. We compared nonsurgical periodontal treatment and lifetime maintenance treatment with no treatment of periodontal disease in patients with periodontal disease and newly diagnosed T2DM. In the treatment scenario, the dentist provides scaling and root planing and the patient commences lifetime maintenance therapy with re-treatment where necessary. In the no-treatment scenario the patient receives only a routine scale and polish as part of regular dental care.
In the base case we considered patients with life expectancies of 28, 17 and 8 years at diagnosis, corresponding to a male (female) aged 46 (49), 58 (61) or 69 (72), respectively. These life expectancies reflect typical ages at diagnosis in the UK and resulting life expectancy assuming T2DM reduces life expectancy by 7 years (Morgan, Currie, & Peters, 2000) . Guided by the reporting of results from diabetes models, we considered patients with baseline HbA1c in three ranges: 7-7.9%, 8%-8.9%, and 9%-9.9%.
Lifetime costs for each patient cohort were estimated as the cost of any periodontal treatment (including maintenance therapy) plus the cost of replacing teeth lost because of periodontitis plus the cost savings (negative costs) arising from any improvement in HbA1c. Gains in QOL were accrued from sustained improvement in HbA1c and quantified in QALYs. Dental costs were discounted at a rate of 3.5% per year following good practice recommendations. Costs and QALY gains associated with a change in HbA1c which were derived from published sources were already discounted. Discounting future costs and benefits reflects societal time preference to bring forward consumption and delay payment.
Results are reported as Incremental Cost-Effectiveness Ratios (ICERs). An ICER is derived by calculating the difference in costs between treatment and control and dividing by the difference in outcomes, and represents the efficiency of the intervention in generating health gains (Detsky & Naglie, 1990) . The resulting cost per QALY can be compared with accepted thresholds -in the UK, health care interventions delivering additional QALY gains at less than £20,000 to £30,000 per QALY are considered cost-effective (McCabe et al., 2008) .
| Effectiveness of non-surgical periodontal treatment
We assumed periodontal therapy is delivered in two 60 min sessions by a practitioner with experience of undertaking periodontal treatment in primary care. Regular maintenance therapy then commences consisting of a 30 min hygienist appointment every 3 months. We assumed the patient would require retreatment for periodontal disease once every 3 years, which could be provided at the patient's primary practice in a 60 min session. Compliance with maintenance therapy of 11%-70% of patients has been reported (Fardal, Johannessen, & Linden, 2003; Pretzl et al., 2009; Ramseier et al., 2014) . We assumed 30% compliance and examined a range of values in sensitivity analysis. We assumed that non-compliant patients would incur the costs of initial treatment only, and would gain no health benefits. We assumed that 87% of compliant patients would respond well to treatment and be able to maintain their periodontal health (Lorentz, Miranda Cota,
Clinical Relevance
Scientific rationale for the study: Clinical evidence indicates a link between periodontal disease and elevated blood glucose levels. Systematic review of interventions to control periodontal disease suggests they may be effective in lowering blood glucose levels. We model the potential costeffectiveness of non-surgical periodontal treatment in patients with diabetes.
Principal findings: If reductions in blood glucose from successful periodontal treatment are maintained the resulting health benefits may be sufficient to justify the cost of treatment at commonly accepted cost-effectiveness thresholds.
Practical implications: Assessment and control of periodontal disease should be included in treatment guidelines for patients diagnosed with diabetes.
Cortelli, Vargas, & Costa, 2009 ). The remaining 13% were assumed to incur the full cost of treatment and maintenance therapy and gain no health benefits.
Rates of tooth loss of 0.01 to 0.28 teeth a year have been reported in patients undergoing treatment including maintenance for periodontal disease (Fardal, Johannessen, & Linden, 2004; Hirschfeld & Wasserman, 1978; Martin, Page, Kaye, Hamed, & Loeb, 2009; Martin, Page, Loeb, & Levi, 2010; Nabers, Stalker, Esparza, Naylor, & Canales, 1988; Ng, Ong, Lim, Koh, & Chan, 2011) . The large variability has been ascribed to differences in disease severity across studies (Martin et al., 2010) . We used a rate of 0.036 teeth lost per year due to periodontal disease in a patient population mostly compliant with maintenance therapy (Fardal et al., 2004) . Data on tooth loss in patients with untreated periodontal disease have been reported (Martin et al., 2014) .
These data indicate a mean rate of 0.19 teeth lost per year for patients with moderate or high risk factors, representative of a population with T2DM.
The impact of periodontal treatment on HbA1c has been the subject of a number of recent reviews and meta-analyses (Botero et al., 2016; Faggion et al., 2016) . There is consistent evidence of an absolute decrease in HbA1c over shorter follow-up (typically 3 months) ranging from −0.24% (Wang, Jen, Chou, & Lei, 2014) to −1.03% (Sun et al., 2014) with most studies reporting decreases in the range −0.3% to −0.5%. We selected a conservative estimate from a robust Cochrane review and meta-analysis (Simpson et al., 2015) . That study reported an absolute decrease of −0.29% at 3-4 months, a decrease similar to that observed from engagement in moderate exercise (Umpierre et al., 2011) . Evidence of a sustained decline in HbA1c is weaker; at 6 months estimates from meta-analyses range from 0.02% (Simpson et al., 2015) to −1.18% (Sun et al., 2014) . We assumed that the absolute decrease in HbA1c of −0.29% observed at 3-4 months is 
| Costs
We took a provider perspective and considered costs falling on health care and dental care providers. In the UK, publicly funded dental primary care is provided by contractors and remunerated according to Units of Dental Activity (UDAs) which are predetermined by procedure. Payment for UDAs is negotiated with the local health authority, but is typically £25 per UDA (British Dental Association, 2013 ).
In addition, around half of adults make a co-payment which is tiered according to the complexity of the procedure. Periodontal treatment would attract three UDAs. We considered it unlikely that £75 would cover the costs to the provider. We estimate the true costs to the provider but note costs to the public sector are lower. In a sensitivity analysis we exclude costs borne by the patient through co-payments.
Dental care costs were calculated on the basis of clinician time to provide the treatment. Hourly rates were taken from an authoritative source and include the cost of all overheads, training and qualifications (Curtis & Burns, 2016) . For periodontal treatment we applied the unit cost of £207 per hour of patient contact time for a providingperformer (practice partner); this assumes a salary of £116,700 reflecting specialist experience and includes associated practice costs such as dental nurse, receptionist and office costs. For restorative treatment following tooth loss we applied the unit cost for a performer only (employee); this assumes a salary of £60,600. However, we modified this cost to include the same associated practice costs as those given for a provider-performer, generating a unit cost of £167 per patient contact hour. We assumed the same hourly cost for a hygienist as a T A B L E 1 DiabForecaster predictions of Quality Adjusted Life-Year gains and costs saved for a 1% absolute decline in HbA1c bridge, 40% removable partial denture, 15% no replacement (gap).
This generated a mean cost for tooth loss of £295 in total, and £181 net of patient co-payments.
| Sensitivity analysis
Univariate sensitivity analysis was undertaken on all model parameters. Ranges were selected for each parameter based on published confidence intervals, where available, or on the range of values published. Table 3 total annual maintenance times reported therein. The upper value for tooth loss in the absence of successful periodontal treatment is that reported for Sri Lankan tea plantation workers (Löe, Anerud, Boysen, & Morrison, 1986 ), a population likely to have had high rates of diabetes; the lower value was taken from a US study (Becker, Berg, & Becker, 1979) . The lower value for the mean cost of replacing lost teeth was derived by assuming 25% of patients receive a resin-bonded bridge, 25% a removable denture and 50% no replacement (gap); the upper value was derived by assuming the highest reported time taken for resin-bonded bridges (200 min) and removable dentures (145 min) in Pennington et al. (2011) . Results are reported in the form of a tornado T A B L E 2 Estimated costs of dental care T A B L E 3 Parameter ranges used in univariate sensitivity analysis (Figure 1) plot and based on a patient with life expectancy of 17 years and an initial HbA1c level of 7%-7.9%. Sensitivity analysis was also undertaken in which costs falling on patients through co-payments were excluded. 
| RESULTS

| DISCUSSION
Our analysis indicates periodontal treatment increases the overall costs associated with the management of periodontal disease.
The cost savings arising from reduced tooth loss are modest when set against lifetime periodontal treatment and maintenance costs.
However, the health benefits attributable to reductions in HbA1c in patients with T2DM are sufficient to justify the additional costs in the majority of patient subgroups we examined. Methods to quantify the QALY gains from dental treatments are insufficiently developed to facilitate inclusion in our analysis. However, a disability weight (reduction in quality of life) of 0.008 for periodontitis was estimated in the Global Burden of Disease Study (Salomon et al., 2013) , and severity of disease is linked to worsening outcomes (Buset et al., 2016) . ease. We found that periodontal treatment costs were only partially offset by savings in restorative dentistry costs. However, we applied a considerably lower cost of £295 for tooth replacement reflecting typical restorative costs in UK publicly funded practice.
| Strengths and limitations of the analysis
Our analysis utilised the best available evidence on the impact of periodontal treatment on HbA1c levels. Unit costs were estimated F I G U R E 1 Impact on the Incremental Cost-effectiveness Ratio of one-way sensitivity analysis in which each model parameter was varied across the range specified in Table 3 on the basis of hourly costs for dentists and hygienists derived from an authoritative UK source and current lab-work charges. We utilised a well-recognised model for estimating the long term costs and consequences of reductions in HbA1c. We made conservative assumptions regarding the proportion of patients complying with maintenance therapy and the impact of foregoing maintenance therapy.
We also chose conservative estimates of tooth loss in the absence of treatment.
Our analysis is subject to a number of limitations. First and foremost we have assumed that beneficial impacts of periodontal treatment on HbA1c levels are maintained for the remainder of the patients' lifetimes provided periodontal disease control is maintained. We used a simple modelling approach, and while we have quantified the impact of individual parameter uncertainty we have not undertaken a probabilistic analysis which would have conveyed the joint impact of parameter uncertainty. Our ability to explore differences across patient subgroups was limited. The published results from DiabForecaster do not differentiate by age. Hence, we had to apply the same cost savings and QALY gains from improved HbA1c control to each of the three age subgroups in our analysis. This assumption is likely to magnify differences in cost-effectiveness across age groups. Our analysis ignores any oral health benefits of improved periodontal disease control, an omission likely to underestimate the cost-effectiveness of periodontal treatment. We have not explicitly considered the impact of periodontal treatment on the costs of managing patients with extensive suppuration; if effective periodontal treatment mitigates these costs then our analysis will have underestimated cost-effectiveness. Treatment costs are estimated in a UK setting which may limit the transferability of findings across jurisdictions.
| CONCLUSIONS
The beneficial effect of treating periodontal disease on HbA1c alone may be sufficient to justify treatment in patients with T2DM at accepted cost-effectiveness thresholds in the UK. Given the additional oral health benefits and high prevalence of periodontal disease in T2DM
patients there is a strong case for inclusion of periodontal assessment and treatment in clinical guidelines for the management of T2DM.
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